Phospholipase A2 as targets for anti-cancer drugs |
| |
Authors: | Cummings Brian S |
| |
Affiliation: | Department of Pharmaceutical and Biomedical Sciences, University of Georgia, Athens, GA 30602, USA. bsc@rx.uga.edu |
| |
Abstract: | Phospholipase A(2) (PLA(2)) are esterases that cleave glycerophospholipids to release fatty acids and lysophospholipids. Inhibition of PLA(2) alters cancer cell growth and death in vitro and PLA(2) expression is increased in breast, lung, and prostate cancers compared to control tissues. Thus, PLA(2) may be novel targets for chemotherapeutics. However, PLA(2) are a diverse family of enzymes, encompassing 19 members. The selectivity of these individual PLA(2) for phospholipids varies, as does their location within the cell, and tissue expression. Thus, their role in cancer may also vary. This review summarizes the expression of individual PLA(2) in cancers, focuses on the potential mechanisms by which these esterases mediate carcinogenesis, and suggests that select PLA(2) isoforms may be targets for anti-cancer drugs. |
| |
Keywords: | BEL, bromoenol lactone COX, cyclooxygenase cPLA2, cytosolic phospholipase A2 CYPP450, cytochrome P450 monooxygneaes EET, epoxyeicosatrienoic acid HETE, hydroxyeicosatetraenoic acid HPETE, hydroperoxyeicosatetraenoic acid iPLA2, Ca2+-independent phospholipase A2 LOX, lipoxygenase LTC4, leukotrienes LysoPLD, lysophospholipid specific phospholipase D NSAID, nonsteroidal anti-inflammatory drugs PAF, platelet activating factor PAF-HA, platelet activating factor-acetylhydrolase PGE2, prostaglandins PGI2, prostacyclins PLA2, phospholipase A2 PPAR, peroxisomal proliferator activated receptor sPLA2, secretory phospholipase A2 TXA2, thromboxanes |
本文献已被 ScienceDirect PubMed 等数据库收录! |
|